AAAscend Advanced TherapiesAscend helps make and sell gene therapy treatments. We know a lot about how to create and share these special medicines.
Biotechnology
GNV
2022
$131M
BTBeacon TherapeuticsBeacon Therapeutics is a biotechnology firm in the clinical stage focused on preserving and enhancing vision for individuals affected by both uncommon and widespread eye disorders. The organization is leveraging the revolutionary potential of gene therapy to achieve significant results for serious eye conditions. Currently, Beacon's pipeline is aimed at severe retinal diseases that cause blindness, including X-linked retinitis pigmentosa (XLRP) and geographic atrophy.
Biotechnology
GNV
2023
$365M
LTLacerta TherapeuticsLacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, Lacerta Therapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.